Vedolizumab effect on liver biochemistry in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease .

Trial Profile

Vedolizumab effect on liver biochemistry in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease .

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Feb 2018

At a glance

  • Drugs Vedolizumab (Primary)
  • Indications Inflammatory bowel diseases; Primary sclerosing cholangitis
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Feb 2018 New trial record
    • 29 Jan 2018 Results published in the Alimentary Pharmacology and Therapeutics.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top